Search results
Search for "Knoevenagel reaction" in Full Text gives 27 result(s) in Beilstein Journal of Organic Chemistry.
Organocatalytic tandem Michael addition reactions: A powerful access to the enantioselective synthesis of functionalized chromenes, thiochromenes and 1,2-dihydroquinolines
- Chittaranjan Bhanja,
- Satyaban Jena,
- Sabita Nayak and
- Seetaram Mohapatra
Beilstein J. Org. Chem. 2012, 8, 1668–1694, doi:10.3762/bjoc.8.191
- (up to 98% de). Later on the same group [71] developed another hydrogen-bond-mediated catalysis for the synthesis of tetrasubstituted thiochromans having three continuous stereocenters 49 following domino thio-Michael–Knoevenagel reaction between 2-mercaptobenzaldehydes 34 and benzylidenemalonates 48
- Córdova and co-workers. Enantioselective tandem Michael–Henry reaction of 2-mercaptobenzaldehyde with β-nitrostyrenes reported by Zhao. Enantioselective tandem Michael–Knoevenagel reaction between 2-mercaptobenzaldehydes and benzylidenemalonates, as developed by the Zhao group. Cinchona alkaloid thiourea
Graphical Abstract
Figure 1: Some representative molecules having chromene, thiochromene or 1,2-dihydroquinolin structural motif...
Figure 2: Screened chiral proline and its derivatives as organocatalysts. Rb = rubidium.
Figure 3: Screened chiral bifunctional thiourea, its derivatives, cinchona alkaloids and other organocatalyst...
Scheme 1: Diarylprolinolether-catalyzed tandem oxa-Michael–aldol reaction reported by Arvidsson.
Scheme 2: Tandem oxa-Michael–aldol reaction developed by Córdova.
Scheme 3: Domino oxa-Michael-aldol reaction developed by Wei and Wang.
Scheme 4: Chiral amine/chiral acid catalyzed tandem oxa-Michael–aldol reaction developed by Xu et al.
Scheme 5: Modified diarylproline ether as amino catalyst in oxa-Michael–aldol reaction as reported by Xu and ...
Scheme 6: Chiral secondary amine promoted oxa-Michael–aldol cascade reactions as reported by Wang and co-work...
Scheme 7: Reaction of salicyl-N-tosylimine with aldehydes by domino oxa-Michael/aza-Baylis–Hillman reaction, ...
Scheme 8: Silyl prolinol ether-catalyzed oxa-Michael–aldol tandem reaction of alkynals with salicylaldehydes ...
Scheme 9: Oxa-Michael–aldol sequence for the synthesis of tetrahydroxanthones developed by Córdova.
Scheme 10: Synthesis of tetrahydroxanthones developed by Xu.
Scheme 11: Diphenylpyrrolinol trimethylsilyl ether catalyzed oxa-Michael–Michael–Michael–aldol reaction for th...
Scheme 12: Enantioselective cascade oxa-Michael–Michael reaction of alkynals with 2-(E)-(2-nitrovinyl)-phenols...
Scheme 13: Domino oxa-Michael–Michael–Michael–aldol reaction of 2-(2-nitrovinyl)-benzene-1,4-diol with α,β-uns...
Scheme 14: Tandem oxa-Michael–Henry reaction catalyzed by organocatalyst and salicylic acid, as reported by Xu....
Scheme 15: Asymmetric synthesis of nitrochromenes from salicylaldehydes and β-nitrostyrene, as reported by San...
Scheme 16: Domino Michael–aldol reaction between salicyaldehydes with β-nitrostyrene, as reported by Das and c...
Scheme 17: Enantioselective synthesis of 2-aryl-3-nitro-2H-chromenes, as reported by Schreiner.
Scheme 18: (S)-diphenylpyrrolinol silyl ether-promoted cascade thio-Michael–aldol reactions, as reported by Wa...
Scheme 19: Organocatalytic asymmetric domino Michael–aldol condensation of mercaptobenzaldehyde and α,β-unsatu...
Scheme 20: Organocatalytic asymmetric domino Michael–aldol condensation between mercaptobenzaldehyde and α,β-u...
Scheme 21: Hydrogen-bond-mediated Michael–aldol reaction of 2-mercaptobenzaldehyde with α,β-unsaturated oxazol...
Scheme 22: Domino Michael–aldol reaction of 2-mercaptobenzaldehydes with maleimides catalyzed by cinchona alka...
Scheme 23: Domino thio-Michael–aldol reaction between 2-mercaptoacetophenone and enals developed by Córdova an...
Scheme 24: Enantioselective tandem Michael–Henry reaction of 2-mercaptobenzaldehyde with β-nitrostyrenes repor...
Scheme 25: Enantioselective tandem Michael–Knoevenagel reaction between 2-mercaptobenzaldehydes and benzyliden...
Scheme 26: Cinchona alkaloid thiourea catalyzed Michael–Michael cascade reaction, as reported by Wang and co-w...
Scheme 27: Domino aza-Michael–aldol reaction between 2-aminobenzaldehydes and α,β-unsaturated aldehydes, as re...
Scheme 28: (S)-Diphenylprolinol TES ether-promoted aza-Michael–aldol cascade reaction, as developed by Wang’s ...
Scheme 29: Domino aza-Michael–aldol reaction reported by Hamada.
Scheme 30: Organocatalytic asymmetric synthesis of 3-nitro-1,2-dihydroquinolines by a dual activation protocol...
Scheme 31: Asymmetric synthesis of 3-nitro-1,2-dihydroquinolines by cascade aza-Michael–Henry–dehydration reac...
An overview of the key routes to the best selling 5-membered ring heterocyclic pharmaceuticals
- Marcus Baumann,
- Ian R. Baxendale,
- Steven V. Ley and
- Nikzad Nikbin
Beilstein J. Org. Chem. 2011, 7, 442–495, doi:10.3762/bjoc.7.57
Graphical Abstract
Figure 1: Structures of atorvastatin and other commercial statins.
Figure 2: Structure of compactin.
Scheme 1: Synthesis of pentasubstituted pyrroles.
Scheme 2: [3 + 2] Cycloaddition to prepare 5-isopropylpyrroles.
Scheme 3: Regiospecific [3 + 2] cycloaddition to prepare the pyrrole scaffold.
Scheme 4: Formation of the pyrrole core of atorvastatin via [3 + 2] cycloaddition.
Scheme 5: Formation of pyrrole 33 via the Paal–Knorr reaction.
Scheme 6: Convergent synthesis towards atorvastatin.
Figure 3: Binding pocket of sunitinib in the TRK KIT.
Scheme 7: Synthesis of sunitinib.
Scheme 8: Alternative synthesis of sunitinib.
Scheme 9: Key steps in the syntheses of sumatriptan and zolmitriptan.
Scheme 10: Introduction of the N,N-dimethylaminoethyl side chain.
Scheme 11: Japp–Klingemann reaction in the synthesis of sumatriptan.
Scheme 12: Synthesis of the intermediate sulfonyl chlorides 62 and 63.
Scheme 13: Alternative introduction of the sulfonamide.
Scheme 14: Negishi-type coupling to benzylic sulfonamides.
Scheme 15: Heck reaction used to introduce the sulfonamide side chain of naratriptan.
Scheme 16: Synthesis of the oxazolinone appendage of zolmitriptan.
Scheme 17: Grandberg indole synthesis used in the preparation of rizatriptan.
Scheme 18: Improved synthesis of rizatriptan.
Scheme 19: Larock-type synthesis of rizatriptan.
Scheme 20: Synthesis of eletriptan.
Scheme 21: Heck coupling for the indole system in eletriptan.
Scheme 22: Attempted Fischer indole synthesis of elatriptan.
Scheme 23: Successful Fischer indole synthesis for eletriptan.
Scheme 24: Mechanistic rationale for the Bischler–Möhlau reaction.
Scheme 25: Bischler-type indole synthesis used in the fluvastatin sodium synthesis.
Scheme 26: Palladium-mediated synthesis of ondansetron.
Scheme 27: Fischer indole synthesis of ondansetron.
Scheme 28: Optimised Pictet–Spengler reaction towards tadalafil.
Figure 4: Structures of carvedilol 136 and propranolol 137.
Scheme 29: Synthesis of the carbazole core of carvedilol.
Scheme 30: Alternative syntheses of 4-hydroxy-9H-carbazole.
Scheme 31: Convergent synthesis of etodolac.
Scheme 32: Alternative synthesis of etodolac.
Figure 5: Structures of imidazole-containing drugs.
Scheme 33: Synthesis of functionalised imidazoles towards losartan.
Scheme 34: Direct synthesis of the chlorinated imidazole in losartan.
Scheme 35: Synthesis of trisubstituted imidazoles.
Scheme 36: Preparation of the imidazole ring in olmesartan.
Scheme 37: Synthesis of ondansetron.
Scheme 38: Alternative route to ondansetron and its analogues.
Scheme 39: Proton pump inhibitors and synthesis of esomeprazole.
Scheme 40: Synthesis of benzimidazole core pantoprazole.
Figure 6: Structure of rabeprazole 194.
Scheme 41: Synthesis of candesartan.
Scheme 42: Alternative access to the candesartan key intermediate 216.
Scheme 43: .Medicinal chemistry route to telmisartan.
Scheme 44: Improved synthesis of telmisartan.
Scheme 45: Synthesis of zolpidem.
Scheme 46: Copper-catalysed 3-component coupling towards zolpidem.
Figure 7: Structure of celecoxib.
Scheme 47: Preparation of celecoxib.
Scheme 48: Alternative synthesis of celecoxib.
Scheme 49: Regioselective access to celecoxib.
Scheme 50: Synthesis of pazopanib.
Scheme 51: Syntheses of anastrozole, rizatriptan and letrozole.
Scheme 52: Regioselective synthesis of anastrozole.
Scheme 53: Triazine-mediated triazole formation towards anastrozole.
Scheme 54: Alternative routes to 1,2,4-triazoles.
Scheme 55: Initial synthetic route to sitagliptin.
Figure 8: Binding of sitagliptin within DPP-IV.
Scheme 56: The process route to sitagliptin key intermediate 280.
Scheme 57: Synthesis of maraviroc.
Scheme 58: Synthesis of alprazolam.
Scheme 59: The use of N-nitrosoamidine derivatives in the preparation of fused benzodiazepines.
Figure 9: Structures of itraconazole, ravuconazole and voriconazole.
Scheme 60: Synthesis of itraconazole.
Scheme 61: Synthesis of rufinamide.
Scheme 62: Representative tetrazole formation in valsartan.
Figure 10: Structure of tetrazole containing olmesartan, candesartan and irbesartan.
Scheme 63: Early stage introduction of the tetrazole in losartan.
Scheme 64: Synthesis of cilostazol.
Figure 11: Structure of cefdinir.
Scheme 65: Semi-synthesis of cefdinir.
Scheme 66: Thiazole syntheses towards ritonavir.
Scheme 67: Synthesis towards pramipexole.
Scheme 68: Alternative route to pramipexole.
Scheme 69: Synthesis of famotidine.
Scheme 70: Efficient synthesis of the hyperuricemic febuxostat.
Scheme 71: Synthesis of ziprasidone.
Figure 12: Structure of mometasone.
Scheme 72: Industrial access to 2-furoic acid present in mometasone.
Scheme 73: Synthesis of ranitidine from furfuryl alcohol.
Scheme 74: Synthesis of nitrofurantoin.
Scheme 75: Synthesis of benzofuran.
Scheme 76: Synthesis of amiodarone.
Scheme 77: Synthesis of raloxifene.
Scheme 78: Alternative access to the benzo[b]thiophene core of raloxifene.
Scheme 79: Gewald reaction in the synthesis of olanzapine.
Scheme 80: Alternative synthesis of olanzapine.
Figure 13: Access to simple thiophene-containing drugs.
Scheme 81: Synthesis of clopidogrel.
Scheme 82: Pictet–Spengler reaction in the preparation of tetrahydrothieno[3,2-c]pyridine (422).
Scheme 83: Alternative synthesis of key intermediate 422.
Figure 14: Co-crystal structures of timolol (left) and carazolol (right) in the β-adrenergic receptor.
Scheme 84: Synthesis of timolol.
Scheme 85: Synthesis of tizanidine 440.
Scheme 86: Synthesis of leflunomide.
Scheme 87: Synthesis of sulfamethoxazole.
Scheme 88: Synthesis of risperidone.
Figure 15: Relative abundance of selected transformations.
Figure 16: The abundance of heterocycles within top 200 drugs (5-membered rings).
